P17.83 OUTCOMES OF RECURRENT GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB AT A TERTIARY CARE CENTER

Por Stevens, G.H.J., Sakruti, S., Griffin, S., Peereboom, D., Ahluwalia, M.S.
Publicado em 2014

P01.003 Botulinum toxin therapy to improve Tumor Treating Field (TTF) compliance: A case report

Por Stevens, G H J, Bucklan, J, Vidimos, A, Peereboom, D M
Publicado no Neuro Oncol (2018)

P09.05 Treatment outcomes in young patients with glioblastoma: the Cleveland Clinic experience

Por Mohapatra, S., Choi, A., Braun, K., Murphy, E., Chao, S., Suh, J., Stevens, G., Peereboom, D., Xuefei, J., Ahluwalia, M. S.
Publicado no Neuro Oncol (2017)

Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.

Por Doolittle, N. D., Anderson, C. P., Bleyer, W. A., Cairncross, J. G., Cloughesy, T., Eck, S. L., Guastadisegni, P., Hall, W. A., Muldoon, L. L., Patel, S. J., Peereboom, D., Siegal, T., Neuwelt, E. A.
Publicado em 2001